Introduction
The interferons (IFN)' are a group of proteins which regulate a wide spectrum of cell functions and modulate responses to infectious and malignant diseases (1, 2) . Since the discovery of IFN, there has been intensive interest in the application of the modulators for clinical use as both antiviral and antineoplastic agents (3) . Recent The interaction of IFN with susceptible cells is mediated by binding to specific high affinity cell surface receptors, a step which is necessary for the subsequent biological effects of IFN (4) . Cel- lular processes subsequent to the binding of IFN show general similarities with many other polypeptide hormone-receptor systems such as insulin or epidermal growth factor (5, 6) . Interferonreceptor complexes are internalized and degraded intracellularly subsequent to ligand binding (7, 8) . Therefore IFN can modulate the expression of its own receptor in target cells. This phenomenon of ligand-induced down-regulation of IFN receptors has been observed in Daudi (lymphoblastoid), WISH (human amnion), and other cultured cell lines (9) (10) (11) (12) . In addition, we have described the desensitization of IFN a receptors by treatment of a human cell line with IFN y (13) . This clearly results from an indirect mechanism since IFN a and y do not share the same receptor sites ( 14) .
The regulation of IFN receptors by IFN itself has important implications for the clinical use of IFN. The current use of IFN in patients often involves empiric choice of dosage and dosing interval. The optimal dose of IFN necessary to elicit in vivo cellular responses to treatment is not known. In order to further evaluate the therapeutic potential of IFN, it is important to study cellular responses, including the regulation of IFN receptors during IFN therapy.
In the present study, we have investigated the expression of IFN receptors on freshly isolated blood lymphocytes from normal individuals and from patients on IFN therapeutic trials for acute lymphoblastic leukemia and papilloma virus infection. The phenomenon of down-regulation of IFN a receptors by IFN a2 itself was demonstrated both in vitro and in vivo.
Methods
Isolation ofcells. Peripheral blood lymphocytes (PBL) were isolated from healthy volunteers using Ficoll-Hypaque density gradient centrifugation as described (15) . Washed PBL were resuspended in RPMI 1640 medium supplemented with 2% fetal calf serum (Gibco, Grand Island, NY), and containing, per ml, 100 U of penicillin and 100 #g of streptomycin. Tonsillar B-lymphocytes (TBL) were isolated from tonsils (obtained at elective tonsillectomies), and finely minced with a scalpel. The resulting cell suspensions were centrifuged over Ficoll-Hypaque, and the tonsillar lymphocytes obtained were depleted ofT lymphocytes by rosetting with neuraminidase-treated sheep erythrocytes as described (16) . The cells were suspended in RPMI medium and incubated in a tissue culture dish (Falcon) at 370C for 30 min for monocyte depletion. The lymphocytes isolated were incubated in RPMI medium with the addition ofindicated concentrations of IFN a2 (Schering Corp., Bloomfield, NJ) for 18 h or as denoted in the figure legends. Cells left untreated with IFN were incubated for the same period of time and used as controls. Subsequent to the incubation period, the cells were washed with fresh medium and used for binding and affinity-labeling experiments, as described below.
To account for the possibility that prior occupancy of cellular IFN a receptors (by unlabeled IFN a2 in the pretreatment procedure) might be inhibiting the subsequent receptor assay with 25I-IFN a2, the following experiments were performed. After incubation at 370C for 18 h with 1,000 U/ml of IFN a2, the cells were washed with acidic phosphatebuffered saline (PBS) (pH 5.5) for 8 min to release receptor-bound unlabeled IFN a2 (10) . Cells not treated with unlabeled IFN a2 were used as controls. All cells were assayed for '25I-IFN a2 receptor binding as described.
In vivo studies were done on PBL isolated from patients being treated with (20) (21) (22) (23) (24) (25) gl) were mixed with an equal volume of electrophoresis buffer (containing I mM dithiothreitol and 2-mercaptoethanol), boiled for 5 min, and subjected to sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE) using 7.5% gels (18). Gels were dried under vacuum, and exposed to XAR film ( Cells were treated with IFN a2, and subsequent '25I-IFN a2 binding assays were performed as described in Fig. 1 . Inset axis as in Fig. 1 . o, Control; ., IFN pretreated. a2 in pretreatment, i.e., 50 U/ml and 200 U/ml, the reduction in binding is less pronounced than that observed with 1,000 U/ ml pretreatment (Fig. 3 ). At these lower pretreatment concentrations (Fig. 3) 15 20 lation. In a representative experiment (Fig. 1 B) bound with 125I-IFN a2, the prebound ligand is covalently linked to the moieties of the receptor which are responsible for the binding of ligand. Subsequent disruption of the plasma membrane by cell lysis buffer releases the 125IIFN a2-receptor complexes, which can be resolved and visualized by SDS-PAGE and autoradiography. This analysis yields sensitive qualitative information on the expression of cell surface IFN receptors. TBL, when preincubated for a period of 3 h with IFN a2 at a concentration of 1,000 U/ml, showed ligand-induced downregulation of IFN a receptors (Fig. 4, lane 2) . When incubated in IFN-free RPMI medium, following receptor downregulation, cells showed a gradual recovery of '25I-IFN a2 binding activity over a 22-h period (Fig. 4, lanes 3-5) .
The complete recovery of receptors in PBL took 72 h, as demonstrated by cellular binding assays (Fig. 5) (Fig. 6 ). Cellular binding assays were performed on these cells in order to generate specific binding curves for the quantitative determination of receptor sites. In this experiment, the control PBL exhibited 480±70 receptor sites/cell (Fig. 6, lane 2) . With IFN a2 pretreatment (followed by acidic PBS wash), both affinitylabeling and cellular binding assays did not detect any receptor expression (Fig. 6, lane 3) . These pretreated cells, when allowed to recover in IFN-free medium, exhibited 227±29 receptor sites per cell after 22 h of incubation (Fig. 6, lane 4) . However, in the presence of actinomycin D (final concentration at 1 jg/mi), the recovery of IFN receptor binding was minimal, i.e., 70±10 receptor sites/cell. This result (Fig. 6, lane 5) suggests that the recovery of IFN binding activity, following down-regulation, requires messenger RNA (mRNA) synthesis. number of IFN a receptors on the PBL of a patient with condyloma acuminata (due to papilloma virus infection) was 834±160 per cell prior to IFN therapy (Fig. 7) . With the progression of therapy, the receptor number decreased to 262+42, 72±8, and 220±40 on day 5, day 19, and day 25 of IFN therapy respectively (Fig. 7) . A similar reduction in IFN receptor binding to PBL during IFN therapy was also observed in the other two patients with either papilloma virus infection or acute lymphoblastic leukemia (Table II) (Fig. 6 ) and thus synthesis ofnew receptor mRNA might be required for this recovery. The in vivo studies reported here on patients receiving IFN therapy revealed a similar phenomenon of reduction in IFN binding (Fig. 7) . Concurrent with the progression of therapy, the IFN binding activities in the patients' PBL were further reduced. This reduction in binding most likely results from IFNinduced downregulation ofIFN receptor expression in vivo during IFN therapy. However, we cannot exclude the possibility of a loss ofan IFN-responsive cellular population in the peripheral circulation during therapy. This latter explanation seems less likely, as our in vivo findings were entirely similar to those of the in vitro observations on downregulation.
The events occurring at the cell surface receptor level are undoubtedly important in the regulation of IFN actions. Two recent studies have demonstrated that natural killer cell activity from patients under continuous IFN therapy are reversibly refractory to in vitro stimulations by IFN (31, 32) . Similarly, a reversible resistance to IFN action has been observed in vitro in transformed mouse fibroblasts during continuous IFN exposure (33) . Gupta et al. demonstrated that the IFN-induced synthesis of specific polypeptides in human cells reaches a maximum within the first few hours of prolonged IFN treatment. This is followed by a refractory period during which there is a decline in IFN-induced protein synthesis (34 
